

Unhealthy Alcohol Use Is Associated With Suboptimal Adherence to Isoniazid Preventive Therapy in Persons With HIV in Southwestern Uganda

Winnie R. Muyindike, MBChB, MMED,^{a,b} Robin Fatch, MPH,^c Debbie M. Cheng, ScD,^d
Nneka I. Emenyonu, DrPH, MPH,^c Leah Forman, MPH,^d Christine Ngabirano, BA(SS), MPH,^a
Julian Adong, MBChB, MMED,^a Benjamin Linas, MD, MPH,^e Karen R. Jacobson, MD, MPH,^e and
Judith A. Hahn, MA, PhD^c

Background: Unhealthy alcohol use is associated with increased progression to tuberculosis (TB) disease, but its effect on adherence to isoniazid (INH) preventive therapy is not known.

Methods: This was a prospective study of persons with HIV with latent TB in southwestern Uganda reporting any current (previous 3 months) alcohol use or no alcohol consumption in the previous year (2:1 ratio). All received INH. We defined suboptimal adherence as <90% of days with at least 1 Medication Event Monitoring System cap opening, over the previous 90 days. Alcohol use was categorized as follows: none: no self-report and phosphatidylethanol (PEth) <8 ng/mL; moderate: Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) 1–2 (women) or 1–3 (men) and/or PEth 8 ≥ 50 ng/mL; and unhealthy: AUDIT-C ≥3 (women) or ≥4 (men) and/or PEth ≥50 ng/mL. We used generalized estimating equation logistic regression analyses to assess the association between the level of alcohol use and suboptimal INH adherence.

Results: Three hundred two persons were enrolled; 279 were on INH for 3 or more months. The prevalence of suboptimal INH adherence was 31.3% at 3 months and 43.9% at 6 months. The odds of suboptimal INH adherence were higher for unhealthy (adjusted odds ratio, 2.78; 95% confidence interval: 1.62 to 4.76) and moderate (adjusted odds ratio, 1.59; 95% confidence interval: 0.94 to 2.71) compared with no alcohol consumption.

Conclusions: Suboptimal adherence to INH at 3 and 6 months was high among prospective study of persons with HIV and associated

with unhealthy alcohol use. Adherence support and alcohol reduction strategies are needed for this group at high risk for active TB.

Key Words: adherence, alcohol use, isoniazid preventive therapy, persons with HIV, phosphatidylethanol, Uganda

(*J Acquir Immune Defic Syndr* 2022;91:460–468)

INTRODUCTION

The World Health Organization (WHO) recommends isoniazid (INH) as a major management strategy for the prevention of tuberculosis (TB) disease among persons with HIV (PWH).^{1,2} Uganda is a high HIV/TB burden country,¹ with TB incidence estimated at 200 persons per 100,000 in 2019¹ and an HIV prevalence of 5.8% among adults aged 15–49 years.³ TB disease may result from infection with *Mycobacterium tuberculosis* leading to primary progression within the first 2 years or from later reactivation of latent TB infection (LTBI).^{4–6} Reactivation occurs more often in people with compromised immune systems,⁷ such as PWH, than in people with intact immune systems just as does primary progression to TB. In sub-Saharan Africa (SSA), the prevalence of LTBI in the general population ranges from 31% to 55%^{8–10} and was estimated at 28% in PWH in Uganda.¹¹ TB preventive therapy with INH is important for PWH and has been reported to decrease mortality by 30%–50% above and beyond the benefits of antiretroviral therapy (ART).^{12–16} In addition, because TB is airborne, preventing TB in PWH also protects the families and community members of PWH. An effective isoniazid preventive therapy (IPT) course encompasses INH initiation, optimal adherence, monitoring for any toxicities, and treatment completion; hence, initiating IPT among PWH may be insufficient without understanding how persons tolerate it, adhere, and/or complete the course prescribed.

Several meta-analyses have found that alcohol use is associated with decreased ART adherence^{17,18}; however, although both infections are fatal if untreated, TB disease differs from HIV in that it is a short-term illness and curable, whereas HIV is lifelong and not curable. Thus, the impact of alcohol use on INH preventive therapy (IPT) adherence, whose time-limited course may make it easier to take than lifelong ART medications, is unclear. In Uganda, although

Received for publication January 14, 2022; accepted July 27, 2022.

From the ^aMbarara University of Science and Technology, Mbarara, Uganda; ^bMbarara Regional Referral Hospital, Mbarara, Uganda; ^cUniversity of California, San Francisco, San Francisco, CA; ^dBoston University School of Public Health, Boston, MA; and ^eBoston Medical Center, Boston, MA.

This study was funded by NIH/NIAAA U01 AA020776 (PI: J.A.H.), NIH/NIAAA K24 AA022586 (PI: J.A.H.), and NIH/NIAAA U24AA020779 (PI: D.M.C.)

The authors have no conflicts of interest to declare.

The data sets generated during and/or analyzed during the current study are not publicly available but are available from the corresponding author and/or the senior author (J.A.H.: judy.hahn@ucsf.edu) on reasonable request.

Correspondence to: Winnie R. Muyindike, MBChB, MMED, Mbarara University of Science and Technology, P.O. Box 1410, Mbarara Uganda (e-mail: wmuyindike@gmail.com).

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

about 60% of adults (age 15 years and older) report abstinence to alcohol in the previous 12 months, those who drink alcohol have a high average pure alcohol consumption.¹⁹ Heavy alcohol users have a 2.5 increased risk for TB disease compared with others^{20,21} and also have an increased risk for poorer TB outcomes including mortality,²² meaning prevention of disease may be particularly impactful. Approximately 25%–30% of PWH in SSA and beyond engage in unhealthy alcohol use, that is, drinking above recommended safe limits.^{23–27} Use of IPT among PWH with unhealthy alcohol use may be affected by reduced adherence as in those using ART with subsequent likelihood of reducing its overall effectiveness.

There is sparse literature about how different levels of alcohol use affect adherence to TB preventive medicines among persons with or without HIV. We sought to (1) determine IPT adherence using Medication Event Monitoring System (MEMS) caps among PWH on ART in southwestern Uganda overall and by level of alcohol use and (2) evaluate factors associated with suboptimal adherence to IPT. We hypothesized that participants with current unhealthy alcohol use would have higher odds of suboptimal adherence to IPT.

METHODS

Study Setting and Population

The data were collected during baseline and follow-up visits of the Alcohol Drinkers' Exposure to Preventive Therapy for TB (ADEPTT) study, which is part of the Uganda Russia Boston Alcohol Network Alcohol Research Collaboration for HIV research (NCT03302299). The study participants were PWH enrolled at the Immune Suppression Syndrome Clinic of Mbarara Regional Referral Hospital in southwestern Uganda from May 2017 to January 2020. The primary aim of the ADEPTT study was to estimate the rate of hepatotoxicity to 6 months INH treatment among PWH who are ≥ 18 years, have LTBI, and reported current (previous 3 months) alcohol use ($n = 200$), with a comparison group not engaged in alcohol use in the previous year ($n = 100$), and to examine the rate of hepatotoxicity by level of alcohol use.

Eligibility Criteria

PWH were eligible if they were a patient at the Mbarara Regional Referral Hospital Immune Suppression Syndrome Clinic, age ≥ 18 years, were fluent in English or Runyankole (the local language), were on a nonnevirapine containing ART regimen for at least 6 months, lived within 2 hours travel time from the clinic with no plans to move, showed no evidence of active TB infection based on WHO symptoms criteria, had no previous use of TB medicines for treatment and/or prevention of TB, reported either current (previous 3 months) alcohol use or abstaining for at least 1 year, including lifetime abstaining, had alanine aminotransferase (ALT) and aspartate aminotransferase (AST) $\leq \times 2$ of the upper limit of normal (ULN), and were not pregnant (after September 2018) (because of a report on poor birth outcomes among women on IPT in pregnancy²⁸). We placed a tuberculin skin test (TST) on each potential

participant using 0.1 mL containing 5 tuberculin units of purified protein derivative. A TST was considered positive if ≥ 5 mm²⁹ within 72 hours of placement. Participants who had a positive TST were eligible to enroll.

Study Procedures

The follow-up visits were every 2 weeks in the first month followed by monthly until the IPT was completed (within 9 months of initiation). Participants were monitored for toxicity and adherence using clinical monitoring and laboratory liver enzyme tests at each study visit. For participants with adverse events such as hepatotoxicity, grading of the event determined the frequency of monitoring visits thereafter and/or cessation of IPT. IPT was stopped if a participant developed any grade 3 or 4 adverse event³⁰ while on INH. At baseline and 3 and 6 months, a structured questionnaire was administered by clinical research assistants. The laboratory measures performed at baseline included a CD4 count, viral load count, and dried blood spots for the phosphatidylethanol (PEth) test. PEth was repeated at 3 and 6 months for participants who self-reported alcohol use at any visit or who tested PEth positive (≥ 8 ng/mL). The dried blood spots were stored at -80°C until shipping to the US Drug Testing Laboratory in Des Plaines, IL, for liquid chromatography with tandem mass spectrometry test for PEth, an abnormal phospholipid formed only in the presence of alcohol.³¹ PEth testing measured the 16:0/18:1 homologue with a limit of quantification of 8 ng/mL, using standard procedures.³¹ At baseline, 2-week visit and monthly, ALT and AST tests were performed. Dosing event histories from the MEMS bottle caps were downloaded and transferred to the MEMS Adherence Software at each study visit while on INH.

Isoniazid Preventive Therapy

INH was prescribed at a dose of 5 mg/kg with a maximum adult dose of 300 mg/d and was given with pyridoxine to reduce the risk of developing peripheral neuropathy³² at a starting dose of 25 mg per day and could be increased to 50 mg per day when symptoms of peripheral neuropathy were reported.

Main Outcome Variable: Suboptimal Adherence to IPT

We used electronic pill caps (Medication Event Monitoring System pill cap, Aardex version 6, Switzerland) that record each bottle cap opening (date and time). MEMS has been used as the standard for assessment of adherence^{33,34} and in studies of adherence to ART^{35–37} and to TB preventive treatment.^{38,39} We collected MEMS data at all visits while on INH; however, for this analysis, the outcome suboptimal adherence was defined as $< 90\%$ of days with at least 1 Medication Event Monitoring System pill cap opening in the previous 90 days, at 3 and 6 months.

Variables

At baseline, we collected social demographic variables (age, gender, education level, marital status, and literacy) and

tobacco and other drug use using an interviewer-administered structured interview. The interview also assessed social support using the Duke-UNC Functional Social Support scale with a mean score <3 defined as low social support,⁴⁰ HIV symptoms, social desirability using the Marlowe–Crowne Social Desirability Scale (SDS),⁴¹ and symptoms of depression, using the Centers for Epidemiologic Studies of Depression scale (CES-D) with a score of ≥ 16 indicating depression.⁴² We collected self-reported previous 30 days adherence to ART using the single-item rating scale,⁴³ dichotomized as excellent/very good versus good/fair/poor/very poor (suboptimal). ART adherence was measured at baseline, 3 months, 6 months, and then every 6 months until study end. For this analysis, we used ART adherence at 3 and 6 months to coincide with when INH adherence was measured. Other variables were time since HIV diagnosis, time since ART start, and adverse events graded 1–4 (DAIDS Table).³⁰ For this analysis, grade 2 or higher symptoms or liver enzyme elevations (LEEs) were included together: grade 2 or higher symptoms or LEEs $\geq 2 \times$ ULN in the previous 3 months versus none.

Main Independent Variable (Predictor of Interest)

The main independent variable was the level of alcohol consumption defined using a composite measure of self-report and PEth. For self-report, we used the Alcohol Use Disorders Identification Test-Consumption (AUDIT-C),⁴⁴ modified for the previous 3 months to reflect alcohol consumption before each visit, with an AUDIT-C score ≥ 3 for women and ≥ 4 for men considered positive.⁴⁵ Level of alcohol use was defined as none (AUDIT-C = 0 and PEth < 8 ng/mL), moderate (any self-report but AUDIT-C negative, ie, 1–2 for women and 1–3 for men, and/or PEth ≥ 8 ng/mL and < 50 ng/mL), and unhealthy (AUDIT-C positive, ie, a score of 3–12 for women and 4–12 for men, and/or PEth ≥ 50 ng/mL).

Statistical Methods

We included all 3-month and 6-month study visits for which the participants were on INH for the full previous 3 months, excluding visits after INH discontinuation due to grade 3+ toxicities or other unrelated adverse events. We additionally excluded visits where the previous 90 days included the 2020 COVID-19 lockdown restrictions in Uganda instituted between mid-March to mid-May 2020 when participants were advised to pause their INH during the lockdown because we were unable to monitor their liver enzyme elevations per the normal study schedule. We conducted descriptive analyses of all variables, overall and by adherence (suboptimal yes vs. no). We calculated frequencies and proportions for categorical variables, and means and standard deviations and medians with interquartile ranges (IQR) for continuous variables.

We used generalized estimating equation logistic regression models with exchangeable working correlations and report robust standard errors for unadjusted and adjusted analyses of suboptimal adherence. The multivariable model included the following independent variables, chosen a priori: level of alcohol use (main independent variable of interest), age, gender, symptoms of depression, grade 2+ adverse event,

social support, ART adherence, and time on INH. These variables were chosen because of literature citing their association with adherence to either ART or TB treatment/IPT.^{17,18,46–55} We conducted Spearman correlations for all pairs of covariates to assess for collinearity; all correlations were < 0.50 . We also ran the multivariable model stratified by social desirability score (low/moderate vs. high) to explore whether the relationship between alcohol use and INH adherence differs by level of social desirability, which is common in self-reported behaviors.⁵⁶ SDS was dichotomized at the median (low/moderate: SDS ≤ 20 vs. high: SDS > 20).

Finally, we conducted 2 sensitivity analyses. First, we excluded the first 30 days of INH to remove a possible effect of early repetitive openings of the MEMS that may occur when patients are aware they are being monitored as they start taking medications⁵⁷; second, we imputed visit data ($n = 8$ visits) for participants who missed visits (not due to an INH discontinuation). We used multiple imputation through chained equations with 20 imputed data sets to impute missing data. The imputation model included all variables included in the primary analysis. We also conducted 2 exploratory analyses examining possible effect modification by age and sex. Stata version 14.2 was used for all analyses.

Ethical Approvals and Consent to Participate

The ADEPTT study activities were approved by the Ethics Review Boards of Mbarara University of Science and Technology, University of California San Francisco, and Boston University. Administrative approvals were also secured from the President's Office and the Ugandan National Council for Science and Technology and from Clinicaltrials.gov (NCT03302299). All participants gave written informed consent to participate in the study.

RESULTS

Screening and Baseline Characteristics

We approached 1434 participants for ADEPTT study screening; 242 were excluded for reasons that included (but were not mutually exclusive) having baseline elevated AST and/or ALT $\geq 2 \times$ the ULN ($n = 79$), previous active TB ($n = 26$) or use of any TB medicines or IPT ($n = 42$), declining/failing to complete screening ($n = 43$), being on nevirapine ($n = 36$), living out of catchment area ($n = 23$), pregnancy ($n = 10$), having taken alcohol in the past year but not the past 3 months ($n = 8$), and having current active TB or symptoms for active TB ($n = 2$). One thousand two hundred eleven participants received a TST, and of these, 55 participants did not return for purified protein derivative reading within 72 hours and 848 had TST results negative, leaving 308 participants eligible for study enrollment. Six persons declined enrollment leaving 302 participants (2 extra persons in the alcohol abstaining group were enrolled in error but retained for analyses). A comparison between the included 302 persons and the 1132 persons screened but not enrolled in the study did not show any differences by self-reported alcohol consumption, age, or gender.

TABLE 1. Study Participant Characteristics at Baseline (n = 279)*

	N (%)
Age (median [IQR])	40 (34–47)
Gender	
Female	142 (50.9)
Male	137 (49.1)
More than a primary education	
No	203 (72.8)
Yes	76 (27.2)
Married/cohabitating	
No	88 (31.7)
Yes	190 (68.4)
Literate: able to read whole sentence?	
No	76 (27.2)
Yes	203 (72.8)
Low social support	
No	184 (66.0)
Yes	95 (34.1)
ART adherence, previous 30 d	
Excellent/very good	225 (80.7)
Good/fair/poor/very poor	54 (19.4)
Alcohol use,† previous 3 mo	
None	77 (27.6)
Moderate	61 (21.9)
Unhealthy	141 (50.5)
Tobacco use, previous 30 days at baseline	
No	245 (87.8)
Yes	34 (12.2)
Self-reported health status	
Good/fair/poor/very poor	149 (53.4)
Excellent/very good	130 (46.6)
Depression	
No	249 (89.3)
Yes	30 (10.8)
Social desirability (median [IQR])	20 (18–22)
Low/moderate (≤20)	141 (50.5)
High (>20)	138 (49.5)
Years since HIV diagnosis (n = 265) (median [IQR])	7 (5–12)

*Includes only study participants who were on INH for 3 months or more.

†Alcohol use: none: no self-report and PEth <8; moderate: any self-report but AUDIT-C negative and/or 8 ng/mL ≤ PEth < 50 ng/mL; and unhealthy: AUDIT-C positive and/or PEth ≥50 ng/mL.

Ninety-two percent (279/302) of participants completed at least 1 study visit at either 3 or 6 months on INH. Reasons for noncompletion included disenrollment due to ineligibility (n = 1), discontinuation before 3 months because of liver or other toxicities (n = 19), and loss to follow-up (n = 3). Of the 279, 50.9% were female, 80.7% reported very good to excellent adherence to ART in previous 30 days at baseline, and 49.5% had high SDS (Table 1). The level of alcohol use was as follows: none: 27.6%; moderate: 21.9%; and unhealthy: 50.5%.

INH Adherence at 3 Months and 6 Months

Suboptimal adherence at 3 and 6 months was 31.3% and 43.9%, respectively. The mean percentage of days with at

least 1 MEMS opening in previous 90 days at 3 and 6 months was 88.9 (SD:16.2) and 81.3 (SD: 24.1), respectively (Table 2). At 3 and 6 months, 44.2% and 58.5% of participants within the unhealthy alcohol group had suboptimal INH adherence, respectively; these proportions were 27.1% and 38.1% for those within moderate alcohol use and 19.8% and 29.8% for no alcohol use. The younger age and the nonliterate participants had higher proportions with suboptimal adherence at both 3 and 6 months.

Unadjusted Analysis

Two hundred seventy-nine participants contributed 539 observations at 3-month and 6-month time points. The participants in the moderate and unhealthy alcohol groups had odds of 1.56 (95% confidence interval [CI]: 0.95 to 2.55) and 2.70 (95% CI: 1.68 to 4.36) of suboptimal adherence, respectively, compared with those with no alcohol use. Other variables that seemed to be associated with suboptimal adherence were age (odds ratio [OR]: 1.05 per 1 year decrease; 95% CI: 1.02 to 1.07), sex (OR for males vs. females: 1.54; 95% CI: 1.01 to 2.34), and ART adherence (OR for very poor/poor/fair/good [suboptimal adherence] vs. very good/excellent: 2.17; 95% CI: 1.35 to 3.48). Adherence decreased over time; the 6-month study visit had increased odds of suboptimal INH adherence (OR: 1.72; 95% CI: 1.34 to 2.21) compared with the 3-month study visit. Participants who were not literate had increased odds for suboptimal adherence compared with those who were literate (OR: 1.65; 95% CI: 1.03 to 2.63), as did participants who reported low/moderate social desirability at baseline, compared with high (OR: 1.54; 95% CI: 1.01 to 2.35). There were no significant differences in adherence among participants by education, marital status, baseline tobacco use, symptoms of depression, health status, with or without grade 2+ LEE or symptoms, and time since HIV diagnosis.

Multivariable Analysis

In multivariable analysis, the global association of the level of alcohol use with suboptimal adherence remained statistically significant; although the adjusted odds for those with moderate alcohol use compared with none was 1.59 (95% CI: 0.94 to 2.71), those with unhealthy alcohol use compared with none had an adjusted odds ratio of 2.78 (95% CI: 1.62 to 4.76) (Table 3). Age, ART adherence, and months on INH remained associated with suboptimal INH adherence, whereas gender was no longer associated with adherence in the adjusted analyses (Table 3).

Additional analysis excluding the first 30 days of INH showed similar results, as did the multiple imputation analysis (data not shown). Adjusted analysis stratified by SDS (median/low vs. high) found that level of alcohol use, age, ART adherence, and months on INH were associated with suboptimal INH adherence in both strata of SDS (Table 4). Finally, we found no evidence of effect modification by either age (interaction *P* = 0.20) or sex (interaction *P* = 0.60) (data not shown).

TABLE 2. Participant Characteristics by INH Adherence at 3 and 6 Months

	3 Months (n = 275)		6 Months (n = 264)	
	≥90%	<90%	≥90%	<90%
	N (%) (n = 189)	N (%) (n = 86)	N (%) (n = 148)	N (%) (n = 116)
Alcohol use,* previous 3 mo				
None	79 (82.3)	17 (19.8)	73 (70.2)	31 (29.8)
Moderate	43 (72.9)	16 (27.1)	26 (61.9)	16 (38.1)
Unhealthy	67 (55.8)	53 (44.2)	49 (41.5)	69 (58.5)
Age (median [IQR])	40 (35–49)	38 (32–44)	41 (35–49)	38 (32–44)
Gender				
Female	102 (72.9)	38 (27.1)	83 (61.9)	51 (38.1)
Male	87 (64.4)	48 (35.6)	65 (50.0)	65 (50.0)
Depression				
No	182 (68.7)	83 (31.3)	140 (56.7)	107 (43.3)
Yes	7 (70.0)	3 (30.0)	8 (47.1)	9 (52.9)
Grade 2+ LEEs or symptoms†				
No	160 (70.2)	68 (29.8)	135 (58.2)	97 (41.8)
Yes	29 (61.7)	18 (38.3)	13 (40.6)	19 (59.4)
Low social support				
No	126 (69.6)	55 (30.4)	97 (55.1)	79 (44.9)
Yes	63 (67.0)	31 (33.0)	51 (58.0)	37 (42.1)
ART adherence, previous 30 d				
Good/fair/poor/very poor	13 (39.4)	20 (60.6)	15 (42.9)	20 (57.1)
Excellent/very good	176 (72.7)	66 (27.3)	133 (58.1)	96 (41.9)
More than a primary education				
No	137 (68.5)	63 (31.5)	106 (55.2)	86 (44.8)
Yes	52 (69.3)	23 (30.7)	42 (58.3)	30 (41.7)
Married/cohabitating				
No	57 (67.1)	28 (32.9)	48 (56.5)	37 (43.5)
Yes	131 (69.3)	58 (30.7)	99 (55.6)	79 (44.4)
Literate: able to read whole sentence?				
No	44 (57.9)	32 (42.1)	32 (48.5)	34 (51.5)
Yes	145 (72.9)	54 (27.1)	116 (58.6)	82 (41.4)
Tobacco use, previous 30 days at baseline				
No	170 (70.5)	71 (29.5)	129 (55.8)	102 (44.2)
Yes	19 (55.9)	15 (44.1)	19 (57.6)	14 (42.4)
Health status				
Good/fair/poor/very poor	98 (71.0)	40 (29.0)	66 (55.0)	54 (45.0)
Excellent/very good	91 (66.4)	46 (33.6)	82 (56.9)	62 (43.1)
Social desirability				

TABLE 2. (Continued) Participant Characteristics by INH Adherence at 3 and 6 Months

	3 Months (n = 275)		6 Months (n = 264)	
	≥90%	<90%	≥90%	<90%
	N (%) (n = 189)	N (%) (n = 86)	N (%) (n = 148)	N (%) (n = 116)
Low/moderate	89 (64.0)	50 (36.0)	67 (50.8)	65 (49.2)
High	100 (73.5)	36 (26.5)	81 (61.4)	51 (38.6)
Years since HIV diagnosis at baseline (median [IQR])	8 (5–12)	7 (4–10)	8 (5–12)	7 (4–10)

*Alcohol use: none: no self-report and PEth < 8; moderate: any self-report but AUDIT-C negative and/or 8 ng/mL ≤ PEth < 50 ng/mL; and unhealthy: AUDIT-C positive and/or PEth ≥ 50 ng/mL.

†Grade 2 or higher symptoms or liver enzyme elevations (LEEs) ≥2x the upper limit of normal, in the previous 3 mo.

DISCUSSION

We found a high level of suboptimal adherence to IPT among a study sample of PWH in southwestern Uganda, enriched for persons reporting current alcohol use, that is, 31.3% and 43.9% at 3 and 6 months of IPT, respectively, with even greater proportions of suboptimal adherence among those with unhealthy alcohol consumption (44.2% and 58.5% at 3 and 6 months, respectively). These proportions are similar to those reported for PWH in a South African study which found 28% with negative urine tests for INH metabolites,⁵⁸ another in PWH in Thailand that reported a 32.5% nonadherence to a 9-month IPT course using the pill count,⁵⁹ and another study among PWH in Brazil and South Africa that recorded that 35% of their patients had no detectable urine INH metabolites.⁴⁶

Our finding of suboptimal IPT adherence among those with unhealthy alcohol use compared with those with no alcohol use is consistent with studies showing the effect of alcohol use on ART adherence^{17,18,47–49} and TB treatment^{50,51} which have also reported that unhealthy alcohol use affects adherence to medicines. As there are strong data citing the association between unhealthy drinking and increased likelihood of progression from LTBI to TB,^{20,21} our data showing suboptimal adherence to IPT among those engaging in unhealthy alcohol use raise concern that poor adherence at the preventive stage may contribute to the increased risk of progression from LTBI to TB disease in this group. Given that a high proportion of PWH in Uganda and other SSA countries engage in unhealthy alcohol use,^{23–27} suboptimal adherence in this group likely impedes the efforts to realize the strategic goal of TB prevention among PWH. There is a need to explore why persons who drink alcohol have more barriers to adherence to medicines and further study and/or optimize use of strategies that have been suggested to improve adherence to medicines among such persons such as contingency management such as incentivizing⁶⁰ or improve on methods previously endorsed by WHO, such as directly observed treatment strategy for TB treatment.

Downloaded from http://journals.lww.com/jaids by BhdMf5ePfkKav1zEumt1QIN4a+KJLhEzGpsH04XM0h0CwWCX1A on 04/25/2024

TABLE 3. Unadjusted and Adjusted ORs* and 95% CIs for INH Adherence <90% in the Previous 3 Months (n = 539 Observations; n = 279 Participants)

	Unadjusted OR (95% CI)	P	Adjusted OR (95% CI)	P
Alcohol use,† previous		<0.01		<0.01
3 mo				
None	1.00		1.00	
Moderate	1.56 (0.95 to 2.55)		1.59 (0.94 to 2.71)	
Unhealthy	2.70 (1.68 to 4.36)		2.78 (1.62 to 4.76)	
Age (per 1 yr decrease)	1.05 (1.02 to 1.07)	<0.01	1.05 (1.02 to 1.08)	<0.01
Gender		0.04		0.38
Female	1.00		1.00	
Male	1.54 (1.01 to 2.34)		1.25 (0.76 to 2.05)	
Depression		0.51		0.37
No	1.00		1.00	
Yes	1.28 (0.61 to 2.67)		1.47 (0.64 to 3.36)	
Grade 2+ LEEs or symptoms‡		0.21		0.17
No	1.00		1.00	
Yes	1.36 (0.84 to 2.19)		1.42 (0.86 to 2.35)	
Low social support		0.96		0.58
No	1.00		1.00	
Yes	0.99 (0.63 to 1.55)		0.87 (0.54 to 1.41)	
ART adherence, previous 30 d		<0.01		<0.01
Good/fair/poor/very poor	2.17 (1.35 to 3.48)		2.45 (1.46 to 4.14)	
Excellent/very good	1.00		1.00	
Study visit		<0.01		<0.01
3 mo	1.00		1.00	
6 mo	1.72 (1.34 to 2.21)		1.86 (1.39 to 2.49)	
More than a primary education		0.68		
No	1.00		—	
Yes	0.91 (0.57 to 1.45)		—	
Married/cohabitating		0.90		
No	1.00		—	
Yes	0.97 (0.62 to 1.53)		—	
Literate: able to read whole sentence?		0.04		
No	1.65 (1.03 to 2.63)		—	
Yes	1.00		—	
Tobacco use, previous 30 d at baseline		0.40		
No	1.00		—	
Yes	1.32 (0.69 to 2.54)		—	

TABLE 3. (Continued) Unadjusted and Adjusted ORs* and 95% CIs for INH Adherence <90% in the Previous 3 Months (n = 539 Observations; n = 279 Participants)

	Unadjusted OR (95% CI)	P	Adjusted OR (95% CI)	P
Health status		0.94		
Good/fair/poor/very poor	1.00		—	
Excellent/very good	1.01 (0.70 to 1.47)		—	
Social desirability		0.05		
Low/moderate	1.54 (1.01 to 2.35)		—	
High	1.00		—	
Time since HIV diagnosis at baseline (per year)	0.93 (0.88 to 0.98)	<0.01	—	

*GEE logistic regression models, exchangeable working correlation with robust empirical standard errors.

†Alcohol use: none: no self-report or PEth < 8; moderate: any self-report but AUDIT-C negative or 8 ≤ PEth < 50; and unhealthy: AUDIT-C positive or PEth ≥ 50.

‡Grade 2 or higher symptoms or liver enzyme elevations (LEEs) ≥2x the upper limit of normal, in the previous 3 months

We also found that participants who reported sub-optimal adherence to ART had increased odds of suboptimal adherence to IPT compared with those who reported very good/excellent adherence to ART, suggesting that the challenges to ART adherence may extend to IPT adherence; the shorter course of medicines for 6 months does not seem to help improve adherence. However, we did find that adherence to IPT declined over time, with a higher proportion of PWH having suboptimal adherence at 6 months compared with the 3 months time point. This was consistent with another study.⁴⁶ These changes over time may be attributed to fatigue that may occur with ingesting medicines over time and suggest that shorter courses of TB preventive therapy such as use of either 3 months of both INH and rifampentine (abbreviated as 3HP) or 1 month of HP, which may have increased opportunities for improved adherence especially among persons who use alcohol with an increased risk of low adherence.^{61,62}

Other studies in SSA cited other reasons that may reduce adherence to IPT including toxicity to the drugs, lack of family and/or household support and health system-related factors such as drug stock outs, poor health worker-patient relationships leading to poor previous patients' education and patient preparation for the treatment,⁵³ and feeling depressed.⁵⁴ We found that decreasing age was associated with higher odds of sub-optimal IPT adherence. Although the literature on IPT and age is sparse, we found consistency with some studies examining adherence to ART,^{52,55} but not all.⁶³ Our study and analyses were, however, not designed to specifically evaluate any association between age or depression and IPT adherence. All the study participants were given the same education message about the reason for IPT before the initial dose of INH.

This study had several limitations and strengths. Although MEMS is considered the near gold-standard

TABLE 4. Adjusted ORs* and 95% CIs for INH Adherence <90% in the Previous 3 Months (n = 539 Observations; n = 279 Participants)—Stratified by the Social Desirability Score at Baseline

	Low/Moderate SDS†		High SDS‡	
	Adjusted OR (95% CI)	P	Adjusted OR (95% CI)	P
Alcohol use,§ previous		0.03		0.04
3 mo				
None	1.00		1.00	
Moderate	1.81 (0.81 to 4.06)		1.37 (0.65 to 2.86)	
Unhealthy	3.03 (1.33 to 6.94)		2.60 (1.22 to 5.54)	
Age (per 1 yr decrease)	1.04 (1.00 to 1.07)	0.04	1.06 (1.01 to 1.10)	0.01
Gender		0.58		0.54
Female	1.00		1.00	
Male	1.21 (0.62 to 2.38)		1.27 (0.59 to 2.76)	
Depression		0.51		0.64
No	1.00		1.00	
Yes	1.30 (0.59 to 2.87)		1.76 (0.16 to 19.12)	
Grade 2+ LEEs or symptoms¶		0.47		0.21
No	1.00		1.00	
Yes	1.29 (0.64 to 2.63)		1.61 (0.77 to 3.37)	
Low social support		0.75		0.60
No	1.00		1.00	
Yes	0.90 (0.47 to 1.73)		0.81 (0.38 to 1.76)	
ART adherence, previous 30 d		0.02		0.01
Good/fair/poor/very poor	2.41 (1.13 to 5.15)		2.47 (1.21 to 5.05)	
Excellent/very good	1.00		1.00	
Study visit		<0.01		<0.01
3 mo	1.00		1.00	
6 mo	1.96 (1.27 to 3.01)		1.76 (1.17 to 2.66)	

*GEE logistic regression models, exchangeable working correlation with robust empirical standard errors.

†n = 271 observations; n = 141 participants.

‡n = 268 observations; n = 138 participants.

§Alcohol use: none: no self-report or PEth < 8; moderate: any self-report but AUDIT-C negative or 8 ≤ PEth < 50; and unhealthy: AUDIT-C positive or PEth ≥ 50.

¶Grade 2 or higher symptoms or liver enzyme elevations (LEEs) ≥2x the upper limit of normal, in the previous 3 months.

measure,³³ it does not inform us about the actual ingestion of the pill hence may not provide perfect information on adherence to medications.^{39,64} In addition, device manipulation, repeated opening, or failure to return the bottles at the set follow-up visits may affect its accuracy. Our study did not record any participant with device manipulation, but we had 13 instances of MEMS bottle/cap misplacement reported as lost or stolen or destroyed by children and 1 case of low battery. The lost or malfunctioning MEMSs were replaced as

soon as the study team received the report. Regardless of the limitations mentioned, the MEMS adherence data that we compiled for previous 3 months encompassed a longer window of IPT adherence compared with some studies that used either self-reported adherence or pill count in recent days to 1 month^{53,65,66} and reported higher adherence levels; our study reported higher levels of suboptimal adherence suggesting that the longer window and the MEMS may be more valid ways to measure adherence. Another limitation of our study is that we recruited participants based on alcohol use (2 persons reporting current alcohol use for each 1 person reporting alcohol abstinence); as such, our estimates of suboptimal adherence may not be representative of a general population sample of PWH. In addition, our study did not collect any qualitative data that may help to distinguish the contributing factors for suboptimal use among ART and/or IPT use and point us to the perceptions of the PWH toward HIV and/or latent TB. We strengthened our study by the use of PEth to augment self-reported alcohol use, which may be under-reported due to social desirability bias,^{67–69} as in previous studies.^{67,70} Our study had very high retention of participants.

Given that unhealthy alcohol use is associated with a 2.5-fold risk of active TB^{20,21} that causes substantial morbidity and mortality and what we found showing that those consuming alcohol at high levels were less likely to adhere to TPT, TPT programs should emphasize alcohol reduction to improve TPT adherence, to reduce the risk of active TB, and to reduce onward TB transmission to the community and families.

In summary, in a sample of PWH on ART in southwestern Uganda enriched for those reporting current alcohol use, about one-third to two-fifths had suboptimal adherence to IPT at 3 and 6 months, with poorer adherence among those engaging in unhealthy alcohol use. We also found poorer IPT adherence among those reporting poorer ART adherence and adherence declined over the course of IPT. These results underscore the urgent need to assess and address alcohol use to increase IPT adherence among PWH and consider shorter TB-preventive courses to have an impact on a highly fatal but preventable disease, TB, among PWH who consume alcohol.

ACKNOWLEDGMENTS

The authors acknowledge all the co-authors of this work for their substantial contribution to the conception and design of study, its performance (W.R.M., C.N., R.F., D.M.C., N.I.E., J.A., B.L., K.R.J., and J.A.H.), data analysis (R.F., L.F., D.M.C., and J.A.H.), and reporting of the work (W.R.M., R.F., DB, C.N., J.A., L.F., N.I.E., K.R.J., B.L., and J.A.H.). The authors also acknowledge the ISS clinic staff at Mbarara Regional Hospital, the study participants, and the research assistants attached to the ADEPT clinical trial for the immense work of collecting the data used.

REFERENCES

1. World Health Organization. *Global Tuberculosis Report 2020*. Geneva, Switzerland: World Health Organization; 2020.

2. World Health Organization. *Global Tuberculosis Report 2015*. Geneva, Switzerland: World Health Organization; 2015.
3. Avert. *HIV and AIDS in Uganda*. 2018. Available at: <https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/uganda>. Accessed 15 April 2020.
4. WHO/UNAIDS. *Policy Statement on Preventive Therapy Against Tuberculosis in People Living With HIV*. Geneva, Switzerland: WHO; 2005.
5. World Health Organization. *Latent Tuberculosis Infection: Updated and Consolidated Guidelines for Programmatic Management*. Geneva, Switzerland: World Health Organization; 2018.
6. Small PM, Hopewell PC, Singh SP, et al. The epidemiology of tuberculosis in San Francisco—a population-based study using conventional and molecular methods. *N Engl J Med*. 1994;330:1703–1709.
7. Getahun H, Matteelli A, Chaisson RE, et al. Latent mycobacterium tuberculosis infection. *N Engl J Med*. 2015;372:2127–2135.
8. Legesse M, Ameni G, Mammo G, et al. Community-based cross-sectional survey of latent tuberculosis infection in Afar pastoralists, Ethiopia, using QuantiFERON-TB Gold In-Tube and tuberculin skin test. *BMC Infect Dis*. 2011;11:89.
9. Mahomed H, Hawkrigde T, Verver S, et al. Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa. *Int J Tuberc Lung Dis*. 2011;15:331–336.
10. Kizza FN, List J, Nkwata AK, et al. Prevalence of latent tuberculosis infection and associated risk factors in an urban African setting. *BMC Infect Dis*. 2015;15:165.
11. Muyindike WR, Fatch R, Cheng DM, et al. Tuberculin skin test positivity among HIV-infected alcohol drinkers on antiretrovirals in south-western Uganda. *PLoS One*. 2020;15:e0235261.
12. Akolo C, Adetifa I, Shepperd S, et al. Treatment of latent tuberculosis infection in HIV infected persons. *Cochrane Database Syst Rev*. 2010;2010:CD000171.
13. Edessa D, Likisa J. A description of mortality associated with IPT plus ART compared to ART alone among HIV-infected individuals in Addis Ababa, Ethiopia: a cohort study. *PLoS One*. 2015;10:e0137492.
14. TEMPRANO ANRS 12136 Study Group, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. *N Engl J Med*. 2015;373:808–822.
15. Ayele HT, Mourik MSM, Debray TPA, et al. Isoniazid prophylactic therapy for the prevention of tuberculosis in HIV infected adults: a systematic review and meta-analysis of randomized trials. *PLoS One*. 2015;10:e0142290.
16. Golub JE, Pronyk P, Mohapi L, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. *AIDS (London, England)*. 2009;23:631–636.
17. Velloza J, Kemp CG, Aunon FM, et al. Alcohol use and antiretroviral therapy non-adherence among adults living with HIV/AIDS in Sub-Saharan Africa: a systematic review and meta-analysis. *AIDS Behav*. 2020;24:1727–1742.
18. Hendershot CS, Stoner SA, Pantalone DW, et al. Alcohol use and antiretroviral adherence: review and meta-analysis. *J Acquir Immune Defic Syndr*. 2009;52:180–202.
19. World Health Organization. *Global Status Report on Alcohol and Health 2018*. Geneva, Switzerland: World Health Organization; 2019.
20. Imtiaz S, Shield KD, Roerecke M, et al. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. *Eur Respir J*. 2017;50:1700216.
21. Rehm J, Baliunas D, Borges GLG, et al. The relation between different dimensions of alcohol consumption and burden of disease: an overview. *Addiction*. 2010;105:817–843.
22. Ragan EJKM, Kleinman MB, Sweigart B, et al. The impact of alcohol use on tuberculosis treatment outcomes: a systematic review and meta-analysis. *Int J Tuberc Lung Dis*. 2020;24:73–82.
23. Duko B, Ayalew M, Ayano G. The prevalence of alcohol use disorders among people living with HIV/AIDS: a systematic review and meta-analysis. *Substance Abuse Treat Prev Policy*. 2019;14:52–59.
24. Wandera B, Tumwesigye NM, Nankabirwa JI, et al. Alcohol consumption among HIV-infected persons in a large urban HIV clinic in Kampala Uganda: a constellation of harmful behaviors. *PLoS One*. 2015;10:e0126236.
25. Thakarar K, Asimwe SB, Cheng DM, et al. Alcohol consumption in Ugandan HIV-infected household-brewers versus non-brewers. *AIDS Behav*. 2016;20:2408–2417.
26. Kader R, Seedat S, Govender R, et al. Hazardous and harmful use of alcohol and/or other drugs and health status among South African patients attending HIV clinics. *AIDS Behav*. 2014;18:525–534.
27. Medley A, Seth P, Pathak S, et al. Alcohol use and its association with HIV risk behaviors among a cohort of patients attending HIV clinical care in Tanzania, Kenya, and Namibia. *AIDS Care*. 2014;26:1288–1297.
28. Gupta A, Montepiedra G, Aaron L, et al. *Randomized Trial of Safety of Isoniazid Preventive Therapy during or after Pregnancy*. Paper presented at: Conference on Retroviruses and Opportunistic Infections, Boston, MA. 2018.
29. Centers for Disease Control and Prevention. *Tuberculin Skin Testing Fact Sheets*. 2017. Available at: <https://www.cdc.gov/tb/publications/factsheets/testing/skintesting.htm#:~:text=The%20Mantoux%20tuberculin%20skin%20test,training%2C%20supervision%2C%20and%20practice>.
30. National Institute of Allergy and Infectious Diseases. *Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0*. North Bethesda, MD: NIAID; 2017.
31. Jones J, Jones M, Plate C, et al. The detection of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoethanol in human dried blood spots. *Anal Methods*. 2011;3:1101–1106.
32. Uganda Ministry of Health. *National Guidelines for Isoniazid Prevention Therapy*. Kampala, Uganda: Uganda Ministry of Health; 2016.
33. Farmer KC. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. *Clin Ther*. 1999;21:1074–1090.
34. van den Boogaard J, Lyimo RA, Boeree MJ, et al. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. *Bull World Health Organ*. 2011;89:632–639.
35. Amsten JH, Demas PA, Farzadegan H, et al. Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring. *Clin Infect Dis*. 2001;33:1417–1423.
36. Hugen PWH, Langebeek N, Burger DM, et al. Assessment of adherence to HIV protease inhibitors: comparison and combination of various methods, including MEMS (electronic monitoring), patient and nurse report, and therapeutic drug monitoring. *J Acquir Immune Defic Syndr*. 2002;30:324–334.
37. Melbourne KM, Geletko SM, Brown SL, et al. Medication adherence in patients with HIV infection: a comparison of two measurement methods. *AIDS Read*. 1999;9:329–338.
38. Fallab-Stubi CL, Zellweger JP, Sauty A, et al. Electronic monitoring of adherence to treatment in the preventive chemotherapy of tuberculosis. *Int J Tuberc Lung Dis*. 1998;2:525–530.
39. Ailinger RL, Black PL, Lima-Garcia N. Use of electronic monitoring in clinical nursing research. *Clin Nurs Res*. 2008;17:89–97.
40. Broadhead WE, Gehlbach SH, De Gruy FV, et al. The Duke-UNC Functional Social Support Questionnaire: measurement of social support in family medicine patients. *Med Care*. 1988;26:709–723.
41. Vu A, Tran N, Pham K, et al. Reliability of the Marlowe-Crowne social desirability scale in Ethiopia, Kenya, Mozambique, and Uganda. *BMC Med Res Methodol*. 2011;11:162–167.
42. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. *Appl Psychol Meas*. 1977;1:385–401.
43. Feldman BJ, Fredericksen RJ, Crane PK, et al. Evaluation of the single-item self-rating adherence scale for use in routine clinical care of people living with HIV. *AIDS Behav*. 2013;17:307–318.
44. Bush K, Kivlahan DR, McDonnell MB, et al. The AUDIT alcohol consumption questions (AUDIT-C): an effective brief screening test for problem drinking. Ambulatory Care Quality Improvement Project (ACQUIP). Alcohol use disorders identification test. *Arch Intern Med*. 1998;158:1789–1795.
45. Bradley KA, DeBenedetti AF, Volk RJ, et al. AUDIT-C as a brief screen for alcohol misuse in primary care. *Alcohol Clin Exp Res*. 2007;31:1208–1217.
46. Kendall EA, Durovni B, Martinson NA, et al. Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV. *AIDS (London, England)*. 2020;34:63–71.
47. Braithwaite RS, Bryant KJ. Influence of alcohol consumption on adherence to and toxicity of antiretroviral therapy and survival. *Alcohol Res Health*. 2010;33:280–287.

48. Fatch R, Emenyonu NI, Muyindike W, et al. Alcohol interactive toxicity beliefs and ART non-adherence among HIV-infected current drinkers in Mbarara, Uganda. *AIDS Behav.* 2017;21:1812–1824.
49. Tran BX, Nguyen LT, Do CD, et al. Associations between alcohol use disorders and adherence to antiretroviral treatment and quality of life amongst people living with HIV/AIDS. *BMC Public Health.* 2014;14:27.
50. Zaman FA, Sheikh S, Das KC, et al. An epidemiological study of newly diagnosed sputum positive tuberculosis patients in Dhubri district, Assam, India and the factors influencing their compliance to treatment. *J Nat Sci Biol Med.* 2014;5:415–420.
51. Shameer M, Manjunath K, Marconi S, et al. A community based case control study on risk factors for treatment interruptions in people with tuberculosis in Kollam district, Kerala, southern India. *Int J Community Med Public Health.* 2016;3:962–967.
52. Newman J, Iriondo-Perez J, Hemingway-Foday J, et al. Older adults accessing HIV care and treatment and adherence in the IeDEA Central Africa cohort. *AIDS Res Treat.* 2012;2012:725713.
53. Mindachew M, Deribew A, Tessema F, et al. Predictors of adherence to isoniazid preventive therapy among HIV positive adults in Addis Ababa, Ethiopia. *BMC Public Health.* 2011;11:916–917.
54. Subbaraman R, Thomas BE, Kumar JV, et al. Understanding nonadherence to tuberculosis medications in India using urine drug metabolite testing: a cohort study. *Open Forum Infect Dis.* 2021;8:ofab190.
55. Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. *AIDS (London, England).* 2004;18:S19–S25.
56. Paulhus DL. Socially desirable responding: the evolution of a construct. In: Braun HI, Jackson DN, Wiley DE, eds. *The Role of Constructs in Psychological and Educational Measurement.* Mahwah, NJ: Lawrence Erlbaum. 2001:51–69.
57. Deschamps AE, Graeve VDE, van Wijngaerden E, et al. Prevalence and correlates of nonadherence to antiretroviral therapy in a population of HIV patients using Medication Event Monitoring System. *AIDS Patient Care STDs.* 2004;18:644–657.
58. Szakacs TA, Wilson D, Cameron DW, et al. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa. *BMC Infect Dis.* 2006;6:97.
59. Ngamvithayapong J, Uthavivoravit W, Yanai H, et al. Adherence to tuberculosis preventive therapy among HIV-infected persons in Chiang Rai, Thailand. *AIDS.* 1997;11:107–112.
60. Herrmann ES, Matusiewicz AK, Stitzer ML, et al. Contingency management interventions for HIV, tuberculosis, and hepatitis control among individuals with substance use disorders: a systematized review. *J Substance Abuse Treat.* 2017;72:117–125.
61. Berhanu RH, Jacobson KR. Tuberculosis preventive therapy for people with HIV Infection in high tuberculosis burden settings: how much is enough? *Ann Intern Med.* 2021;174:1462–1463.
62. Churchyard G, Cárdenas V, Chihota V, et al. Annual tuberculosis preventive therapy for persons with HIV infection: a randomized trial. *Ann Intern Med.* 2021;174:1367–1376.
63. Bianco JA, Heckman TG, Sutton M, et al. Predicting adherence to antiretroviral therapy in HIV-infected older adults: the moderating role of gender. *AIDS Behav.* 2011;15:1437–1446.
64. Samet JH, Sullivan LM, Traphagen ET, et al. Measuring adherence among HIV-infected persons: is MEMS consummate technology? *AIDS Behav.* 2001;5:21–30.
65. Ayele AA, Asrade Atafie S, Balcha DD, et al. Self-reported adherence and associated factors to isoniazid preventive therapy for latent tuberculosis among people living with HIV/AIDS at health centers in Gondar town, North West Ethiopia. *Patient Prefer Adherence.* 2017;11:743–749.
66. Hiransuthikul N, Nelson KE, Hiransuthikul P, et al. INH preventive therapy among adult HIV-infected patients in Thailand. *Int J Tuberc Lung Dis.* 2005;9:270–275.
67. Muyindike WR, Lloyd-Travaglini C, Fatch R, et al. Phosphatidylethanol confirmed alcohol use among ART-naïve HIV-infected persons who denied consumption in rural Uganda. *AIDS Care.* 2017;29:1442–1447.
68. Adong J, Fatch R, Emenyonu NI, et al. Social desirability bias impacts self reported alcohol use among persons with HIV in Uganda. *Alcohol Clin Exp Res.* 2019;43:2591–2598.
69. Bajunirwe F, Haberer JE, Boum Y, et al. Comparison of self-reported alcohol consumption to phosphatidylethanol measurement among HIV-infected patients initiating antiretroviral treatment in southwestern Uganda. *PLoS One.* 2014;9:e113152.
70. Hahn JA, Emenyonu NI, Fatch R, et al. Declining and rebounding unhealthy alcohol consumption during the first year of HIV care in rural Uganda, using phosphatidylethanol to augment self report. *Addiction.* 2016;111:272–279.